Regulatory timelines are inherently unpredictable
Semaglutide (single agonist), tirzepatide (dual agonist), and retatrutide (triple agonist) represent three generations of incretin-based research, each building on the last
References Psichas, A., Sleeth, M
And because the drugs health benefits may take years to materialize such as averting a future heart attack the long-term financial advantages could accrue to other insurers
Choose retatrutide if the research question specifically targets hepatic steatosis, fat oxidation, or the glucagon-axis contribution to energy expenditure, and if you can tolerate a thinner Phase 3 evidence base and longer titration window
Probiotics improve gut health and can help manage some gastrointestinal side effects associated with GLP-1 medications